Outlook Therapeutics, Inc. - Se (OTLKW) Stock Analysis
DELISTED 2022
What happened to Outlook Therapeutics, Inc. - Se (OTLKW) stock?
Outlook Therapeutics, Inc. - Se (OTLKW) no longer trades on public markets. It was delisted in February 2022. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Outlook Therapeutics, Inc. - Se (OTLKW) trades at $0.03. Outlook Therapeutics, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a potential treatment for retinal diseases. Sector: Healthcare.
Last analyzed: Mar 17, 2026Analyst Coverage for OTLKW: OTLKW does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates OTLKW against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
OTLKW: 1/2 scored disciplines lean bearish. Dominant signal: Ken Griffin bullish.
How is this calculated? →Outlook Therapeutics, Inc. - Se (OTLKW) Healthcare & Pipeline Overview
Outlook Therapeutics, Inc. is a biopharmaceutical company specializing in the development of ONS-5010, an ophthalmic formulation of bevacizumab for various retinal diseases. The company aims to address unmet needs in the ophthalmology sector by providing an alternative treatment option to improve vision outcomes.
What Is the Investment Thesis for OTLKW?
The investment thesis for Outlook Therapeutics centers on the potential approval and commercialization of ONS-5010. A key value driver is the addressable market for retinal diseases, including wet AMD, DME, and BRVO. The company's success hinges on securing FDA approval for ONS-5010 and successfully marketing it as a safe and effective alternative to compounded bevacizumab. Key metrics to watch include the progress of regulatory submissions, clinical trial outcomes, and market penetration post-approval. The high profit margin of -50045.1% and gross margin of -588.7% indicate significant challenges. Ongoing catalysts include continued regulatory interactions and potential partnerships. Potential risks include regulatory setbacks, competition from existing treatments, and the company's ability to secure adequate funding.
Based on FMP financials and quantitative analysis
OTLKW Key Highlights
The company is focused on ONS-5010, an ophthalmic formulation of bevacizumab, targeting retinal diseases.
- The primary goal is to obtain regulatory approval for ONS-5010 in the United States and other key markets.
- ONS-5010 is intended as an alternative to compounded bevacizumab products, addressing quality control concerns.
- The company is targeting retinal specialists and ophthalmic surgeons for commercialization.
- The company's P/E ratio is -0.22, indicating that it is not currently profitable.
Who Are OTLKW's Competitors?
OTLKW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| EACQ Easterly Acquisition Corp. | $10.44 | -0.10% | $2.19B | 47 |
| EZT Entergy Texas, Inc. | $25.22 | -0.08% | $1.17B | 46 |
| GATX GATX Corporation | $174.96 | -0.68% | $6.21B | 43 |
| INBXV Inhibrx, Inc. Ex-distribution When-Issued | $30.85 | +0.00% | $1.57B | 46 |
| LMHA Legg Mason, Inc. | $25.70 | -0.50% | $3.11B | 46 |
| VRTX Vertex Pharmaceuticals Incorporated | $540.26 | -2.14% | $137B | 98 |
| REGN Regeneron Pharmaceuticals, Inc. | $835.15 | -0.68% | $86.0B | 94 |
| ALNY Alnylam Pharmaceuticals, Inc. | $229.30 | -5.49% | $30.7B | 92 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are OTLKW's Key Strengths?
Focus on unmet needs in ophthalmology.
- Proprietary formulation of bevacizumab (ONS-5010).
- Potential for regulatory exclusivity.
- Targeted commercialization strategy.
What Are OTLKW's Weaknesses?
Dependence on a single product candidate (ONS-5010).
- Lack of established commercial infrastructure.
- Negative profit and gross margins.
- Limited financial resources.
What Could Drive OTLKW Stock Higher?
Regulatory review of ONS-5010 by the FDA.
- Potential announcement of clinical trial results for ONS-5010 in additional indications.
- Potential strategic partnerships or collaborations.
What Are the Key Risks for OTLKW?
Regulatory rejection or delays for ONS-5010.
- Competition from existing treatments and new entrants.
- Failure to secure adequate funding for clinical trials and commercialization.
- Adverse clinical trial results for ONS-5010.
- The company's negative profit and gross margins raise concerns about its financial sustainability.
What Are the Growth Opportunities for OTLKW?
- Growth opportunity 1: Regulatory Approval and Commercialization of ONS-5010: Securing FDA approval for ONS-5010 represents a significant growth opportunity. The market for wet AMD, DME, and BRVO treatments is substantial, with millions of patients worldwide. Successful commercialization would allow Outlook Therapeutics to capture a share of this market, generating significant revenue. The timeline for this opportunity depends on the FDA review process, with potential approval within the next 1-2 years. The competitive advantage lies in offering an FDA-approved, quality-controlled bevacizumab option.
- Growth opportunity 2: Expansion into Additional Retinal Disease Indications: Beyond wet AMD, DME, and BRVO, ONS-5010 may have potential applications in other retinal diseases. Expanding the label to include additional indications would broaden the addressable market and increase revenue potential. This growth opportunity depends on the results of future clinical trials and regulatory approvals. The timeline for this expansion is likely 3-5 years. The competitive advantage lies in leveraging the existing ONS-5010 formulation and clinical data.
- Growth opportunity 3: Strategic Partnerships and Collaborations: Partnering with larger pharmaceutical companies or distributors could accelerate the commercialization of ONS-5010 and expand its reach into new markets. Strategic collaborations could provide access to additional resources, expertise, and distribution channels. The timeline for this opportunity is ongoing, as the company actively seeks potential partnerships. The competitive advantage lies in leveraging the unique value proposition of ONS-5010 and the company's expertise in ophthalmology.
- Growth opportunity 4: International Expansion: Expanding into international markets represents a significant growth opportunity for Outlook Therapeutics. Obtaining regulatory approvals in Europe, Asia, and other regions would broaden the addressable market and increase revenue potential. This expansion would require additional clinical trials, regulatory submissions, and commercial infrastructure. The timeline for this expansion is likely 3-5 years. The competitive advantage lies in leveraging the existing ONS-5010 formulation and clinical data.
- Growth opportunity 5: Development of Next-Generation Ophthalmic Therapies: Investing in research and development to create next-generation ophthalmic therapies represents a long-term growth opportunity for Outlook Therapeutics. Developing new formulations, delivery systems, or therapeutic targets could position the company as a leader in the ophthalmology space. This growth opportunity depends on the success of future research and development efforts. The timeline for this opportunity is likely 5-10 years. The competitive advantage lies in leveraging the company's expertise in ophthalmology and its commitment to innovation.
What Are OTLKW's Competitive Advantages?
- Regulatory exclusivity for ONS-5010 upon approval.
- Proprietary formulation of bevacizumab.
- Established relationships with retinal specialists and ophthalmic surgeons.
- Potential for patent protection on ONS-5010 and related technologies.
What Does OTLKW Do?
Outlook Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of ONS-5010, an ophthalmic formulation of bevacizumab under development to treat retinal diseases. The company was founded with the goal of providing a new treatment option for patients with unmet needs in the ophthalmology market. ONS-5010 is being developed as an alternative to compounded bevacizumab products, which lack FDA approval and consistent quality control. The company's primary focus is on obtaining regulatory approval for ONS-5010 in the United States and other key markets. Outlook Therapeutics aims to establish a commercial presence in the ophthalmology space, targeting retinal specialists and ophthalmic surgeons. The company is headquartered in Iselin, New Jersey. ONS-5010 is intended to be administered via intravitreal injection for conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO).
What Products and Services Does OTLKW Offer?
- Develops ophthalmic formulations of bevacizumab.
- Focuses on treatments for retinal diseases.
- Seeks regulatory approval for ONS-5010.
- Aims to provide an alternative to compounded bevacizumab.
- Targets retinal specialists and ophthalmic surgeons.
- Conducts clinical trials to evaluate the safety and efficacy of ONS-5010.
- Plans to commercialize ONS-5010 upon regulatory approval.
How Does OTLKW Make Money?
- Develops and seeks regulatory approval for ONS-5010.
- Commercializes ONS-5010 through direct sales and marketing.
- Generates revenue from sales of ONS-5010 to retinal specialists and ophthalmic surgeons.
- Potentially licenses or partners with other companies for distribution.
What Industry Does OTLKW Operate In?
The biotechnology industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. Outlook Therapeutics operates in the ophthalmology segment, which is driven by an aging population and increasing prevalence of retinal diseases. The market for retinal disease treatments is competitive, with established players offering therapies such as anti-VEGF injections. Outlook Therapeutics aims to differentiate itself by providing a quality-controlled, FDA-approved bevacizumab option. The company's success depends on navigating the regulatory landscape and effectively competing with existing treatments.
Who Are OTLKW's Key Customers?
- Retinal specialists
- Ophthalmic surgeons
- Hospitals and clinics
- Patients with retinal diseases
Company Profile
Outlook Therapeutics, Inc. - Se operates in the Biotechnology industry within the Healthcare sector. OTLKW has traded publicly since 2016.
Key Financial Metrics
Return on equity for Outlook Therapeutics, Inc. - Se stands at 163.7%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.39 means current liabilities exceed short-term assets, a liquidity point worth watching.
OTLKW Financials
Bull Case vs Bear Case
Bull Case
- Insider buying lately suggests management believes in the future, which can be a strong signal.
- The community seems to be rallying behind the company's long-term vision.
- Recent developments in the market suggest a growing need for their specific type of treatment.
- Positive community sentiment indicates growing confidence in the company's ability to execute its plans.
Bear Case
- Recent insider activity, while showing buying, could also be interpreted as a move to boost market confidence amidst other challenges.
- Community sentiment, although leaning bullish, still has pockets of strong skepticism about regulatory hurdles.
- Market perception is heavily influenced by upcoming regulatory decisions, creating significant uncertainty.
- Bearish community views highlight concerns about competition and potential delays in product approvals.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
OTLKW Latest News
No recent news available for OTLKW.
Leadership: None
CEO title
Unknown
Track Record: Unknown
Outlook Therapeutics, Inc. - Se Healthcare Stock: Key Questions Answered
What happened to Outlook Therapeutics, Inc. - Se (OTLKW) stock?
Outlook Therapeutics, Inc. - Se (OTLKW) no longer trades on public markets. It was delisted in February 2022. The figures below are historical and are not a current quote.
Can I still buy OTLKW shares?
No. OTLKW stopped trading on public markets in February 2022, so the shares are not available through a broker. Anything you see quoted for OTLKW elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before OTLKW stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Outlook Therapeutics, Inc. - Se. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What are the main risks for OTLKW?
The main risks for Outlook Therapeutics include regulatory setbacks or delays in the approval of ONS-5010, competition from existing treatments and new entrants in the retinal disease market, and the company's ability to secure adequate funding for clinical trials and commercialization. Additionally, adverse clinical trial results for ONS-5010 could negatively impact the company's prospects. The company's negative profit and gross margins also pose a risk to its financial sustainability.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending for OTLKW, limiting the depth of financial and market analysis.
- Limited information available on CEO and leadership team.